Founded in 1949, Medtronic has grown to become the world's largest independent medical technology company. At the core of all we do is our Mission: to alleviate pain, restore health and extend life. It provides a clear path for all employees as we work together to take Medtronic to the next level.
Medtronic was first incorporated April 23, 1957 and became a public company as the result of a convertible debenture offering. The first shares were issued under these debentures on December 17, 1959 to our company founders, Earl Bakken and Palmer Hermundslie. Medtronic shares were traded Over-the-Counter (OTC) until we were listed on the NASDAQ in 1964. Medtronic began trading on the New York Stock Exchange on November 21, 1977 and continues to be traded on the NYSE today under the ticker symbol MDT.
|05/14/13||Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2013|
|MINNEAPOLIS - May 14, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2013 on Tuesday, May 21, 2013. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic's fourth quarter and fiscal year, which ended April 26, 2013. Medtronic will host a webcast at 7 a.m. Central Time to... |
|05/11/13||Biventricular Pacing Reduces Symptoms and Improves Quality-of-Life in AV Block Patients with Heart Failure and Reduced Pumping Function|
|New Medtronic Data Show Additional Clinical Advantages in Pacing Both Ventricles Versus Conventional Right-Ventricular Pacing MINNEAPOLIS and DENVER - May 11, 2013 - Medtronic, Inc. (NYSE: MDT) today announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, significantly improves heart failure symptoms and quality of life in a subset of heart failure patients. Findings from ... |
|05/10/13||Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance Monitoring|
|MINNEAPOLIS and DENVER - May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone (impedance monitoring measures the electrical continuity of a lead four times per day). The retrospective analysis, which focused on Endotak® leads (Boston Scientific) an... |
|Q4 2013 Medtronic Inc. Earnings Release|
|05/21/13 7:00 a.m. CT|